The Phase IIb/III trial will assess the safety and efficacy of mocravimod in acute myeloid leukemia patients. Credit: Paulo Henrique Orlandi Mourao / commons.wikimedia.org.

Priothera has enrolled the first participant in the Phase IIb/III MO-TRANS global trial of mocravimod in acute myeloid leukemia (AML) patients undergoing allogeneic haematopoietic cell transplant (HCT).

The placebo-controlled, double-blind, pivotal study has been designed for evaluating the safety and efficacy of mocravimod as an adjunctive and maintenance therapy for these patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It will assess the relapse-free, as well as overall survival, of two dose levels of mocravimod against a placebo.

The company is commencing the study in the US, Israel, Europe, and in additional Asian and Latin American countries.

The sphingosine 1 phosphate (S1P) receptor modulator, mocravimod’s tolerability, safety, and efficacy have been evaluated in Phase I and Phase II trials in many autoimmune indications.

It is being developed to improve the curative potential of allogeneic HCT.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In an early clinical study, the new investigational drug demonstrated a clinically relevant benefit to haematologic malignancies patients undergoing allogeneic HCT.

Priothera chief medical officer Elisabeth Kueenburg said: “This MO-TRANS global Phase IIb/III study builds on pre-clinical and clinical proof of concept studies, which demonstrated mocravimod’s ability to improve survival outcomes for patients with haematological malignancies requiring allogeneic HCT.

“The mode of action has been well-established in autoimmune indications, but never in haematology. Mocravimod has the potential to be a first-in-class therapy in maintaining the graft-versus-leukemia effect while preventing graft-versus-host disease, one of the most serious complications of allogeneic HCT.

“We expect this trial to deliver important clinical data supporting the registration of mocravimod in this indication.”

The company expects to receive topline data from the Phase IIb/III MO-TRANS global study in 2025.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact